-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎Editor of WuXi AppTec's content team On December 16, 2021, Verge Genomics announced the completion of US$98 million in Series B financing
.
The funds obtained in this round of financing will be used to expand the number of preclinical and clinical projects in the company's product pipeline and advance its pilot projects through clinical trials
.
In addition, Verge will continue to expand its proprietary end-to-end, artificial intelligence (AI)-driven technology platform, which can accelerate many drug discovery steps such as translational medicine and clinical development
.
The "all-in-human" platform developed by Weizhi Gene is based on the brain transcriptomes data set of patients with various neurodegenerative diseases
.
By using AI's "unbiased" algorithm, this platform can provide insights into the causal mechanism of innovative diseases among patient groups segmented based on genetic characteristics to discover therapeutic targets for complex diseases
.
For example, neurological diseases are caused by complex interactions between many genes.
Because only one gene is studied, many previous drug discoveries have failed
.
The Verge's machine algorithm platform can map out hundreds of genes that cause diseases, and then find drugs that target all genes
.
The press release stated that the company's first project will enter the clinic in 2022
.
In July 2021, the company announced that it had reached a potential US$706 million collaboration with Eli Lilly to use its platform to develop new treatments for amyotrophic lateral sclerosis (ALS)
.
▲Ms.
Zhang Xinli, CEO and co-founder of Verge Genomics Related reading: Interview with Zhang Xinli, the 35 largest technology innovators of the year: Seeing opportunities, don’t be afraid to chase Verge Genomics co-founder and CEO Zhang Xinli (Alice Zhang) said: "More and more people are realizing the potential
of
our AI platform for the most challenging disease translation drug discovery .
Our platform has proven that it can identify new targets for these diseases from patient data sets, and quickly integrate It is developed as a drug candidate
.
With the completion of the B round of financing, we can validate our platform in clinical trials and add new clinical data sets, which may significantly improve our self-reinforcement learning platform and accelerate our progress The mission of developing better drugs faster
.
"Reference: [1] Verge Genomics Secures $98 Million in New Financing.
Retrieved December 16, 2021, from https:// /Verge-Genomics-Secures-98-Million-in-New-Financing Disclaimer: WuXi AppTec's content team focuses on introducing global biomedical health research progress
.
This article is for the purpose of information exchange only.
The opinions expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article
.
This article is not a treatment recommendation either
.
If you need guidance on the treatment plan, please go to a regular hospital for treatment
.
.
The funds obtained in this round of financing will be used to expand the number of preclinical and clinical projects in the company's product pipeline and advance its pilot projects through clinical trials
.
In addition, Verge will continue to expand its proprietary end-to-end, artificial intelligence (AI)-driven technology platform, which can accelerate many drug discovery steps such as translational medicine and clinical development
.
The "all-in-human" platform developed by Weizhi Gene is based on the brain transcriptomes data set of patients with various neurodegenerative diseases
.
By using AI's "unbiased" algorithm, this platform can provide insights into the causal mechanism of innovative diseases among patient groups segmented based on genetic characteristics to discover therapeutic targets for complex diseases
.
For example, neurological diseases are caused by complex interactions between many genes.
Because only one gene is studied, many previous drug discoveries have failed
.
The Verge's machine algorithm platform can map out hundreds of genes that cause diseases, and then find drugs that target all genes
.
The press release stated that the company's first project will enter the clinic in 2022
.
In July 2021, the company announced that it had reached a potential US$706 million collaboration with Eli Lilly to use its platform to develop new treatments for amyotrophic lateral sclerosis (ALS)
.
▲Ms.
Zhang Xinli, CEO and co-founder of Verge Genomics Related reading: Interview with Zhang Xinli, the 35 largest technology innovators of the year: Seeing opportunities, don’t be afraid to chase Verge Genomics co-founder and CEO Zhang Xinli (Alice Zhang) said: "More and more people are realizing the potential
of
our AI platform for the most challenging disease translation drug discovery .
Our platform has proven that it can identify new targets for these diseases from patient data sets, and quickly integrate It is developed as a drug candidate
.
With the completion of the B round of financing, we can validate our platform in clinical trials and add new clinical data sets, which may significantly improve our self-reinforcement learning platform and accelerate our progress The mission of developing better drugs faster
.
"Reference: [1] Verge Genomics Secures $98 Million in New Financing.
Retrieved December 16, 2021, from https:// /Verge-Genomics-Secures-98-Million-in-New-Financing Disclaimer: WuXi AppTec's content team focuses on introducing global biomedical health research progress
.
This article is for the purpose of information exchange only.
The opinions expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article
.
This article is not a treatment recommendation either
.
If you need guidance on the treatment plan, please go to a regular hospital for treatment
.
